Firm stops trials of obesity drug

Sanofi-Aventis has discontinued all trials of its anti-obesity drug rimonabant (Acomplia), which was suspended by the European Medicines Agency last month.

At the time of the suspension, Sanofi-Aventis said it saw the suspension as temporary and that it hoped ongoing studies would provide additional evidence for the product's safety and benefit in patients with diabetes and cardiovascular disease.

The company has now announced that it has decided to discontinue the ongoing rimonabant clinical development programme in all indications.

The decision has been taken 'in light of recent demands by certain national health authorities', a spokesman said.

'As a result the feasibility of the global clinical development programme has been compromised.'

The EMEA withdrew the European Marketing Authorisation for Acomplia after an assessment of the drug's benefits and risks showed an increased risk of psychiatric disorders patients.

The agency said it believed that these side-effects could not be adequately addressed by risk minimisation measures.

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Follow Us:

Just published

Woman holding face in pain

Should GPs treat patients presenting with dental problems?

The MDU's Dr Kathryn Leask considers what GPs should do if a patient presents with...

Conservative Party leadership candidate and foreign secretary Liz Truss

Liz Truss vows to resolve GP pension tax crisis if she becomes prime minister

Liz Truss has affirmed her commitment to resolving the GP pensions crisis but has...

Baby receiving a vaccine in their thigh

JCVI advises changes to routine childhood and HPV immunisation schedules

The Joint Committee on Vaccination and Immunisation (JCVI) has recommended a change...

GP consultation

General practice delivering 'up to double the appointments it is paid for'

General practice in England may be delivering as many as double the number of appointments...

Sign outside BMA House

GP suicide sparks calls for measures to protect doctors from spiralling workloads

The government and policymakers must do more to safeguard doctors and NHS staff from...

Talking General Practice logo

Podcast: Living with long COVID

In August we’re bringing you some of the best interviews from series one of the podcast....